Curve Biosciences
PrivateLast Round
Series A
Oct 29, 2025
Est. Valuation
$32.7M
Total Funding Raised
$57.7M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Curve Biosciences operates in Healthcare & Life Sciences and is based in Dallas, Texas. Its latest recorded funding round was a Series A round in October 2025.
Curve Biosciences is a biotechnology company that develops AI-powered blood diagnostics and Whole-Body Blood Tests to monitor organ health and chronic disease progression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Curve Biosciences Comparables
Compare Curve Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 84% | |
| Singlera Genomics Inc. | 81% | |
| Helio Genomics | 80% |
For institutional investors. Book with your work email.
Curve Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 29, 2025 | ||||
| Seed | May 13, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Curve Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LifeX Ventures | Series A |
| NZVC | Seed, Series A |
| LifeX Ventures | Series A |
| LUMA Partners | Series A |
| First Spark Ventures | Seed, Series A |
| Incite Ventures | Seed, Series A |
| Techas Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 300% MoM, reaching 1.6K.
- May 13, 2026
Monthly visitors increased 162% MoM.
For institutional investors. Book with your work email.
Curve Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Curve Biosciences's valuation, stock price, and market status.
Is Curve Biosciences a public or private company?
Curve Biosciences is a private company.
What is the current stock price of Curve Biosciences?
Curve Biosciences is a private company, so its shares have no public market price. Caplight tracks Curve Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Curve Biosciences worth (valuation)?
Curve Biosciences's valuation is estimated at $32.7M based on funding round data.
Can I buy Curve Biosciences stock?
Curve Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Curve Biosciences's last funding round?
Curve Biosciences's most recent funding round was Series A on October 29, 2025.
Who are the main investors in Curve Biosciences?
Key investors in Curve Biosciences include LUMA Partners, Luma Group.
Will Curve Biosciences IPO soon?
No public IPO plans have been announced for Curve Biosciences.
How can I track Curve Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Curve Biosciences's shares on secondary markets.